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Abstract
Antiangiogenesis is a promising anti-tumor strategy through inhibition tumor vascular
formation to suppress tumor growth. Targeting specific VEGF/R has been shown
therapeutic benefits in many cancer types and become a first approved
antiangiogenic modalities by Food and Drug Administration (FDA) in United States.
However, interruption of homeostasis in normal tissues that is likely due to the
inhibition of VEGF/R signaling pathway induces unfavorable side effects. Moreover,
cytostatic nature of antiangiogenic drugs frequently causes less tumor cell specific
killing activity, and cancer cells escaped from cell death induced by these drugs
even gain more malignant phenotypes, resulting in tumor invasion and metastasis.
To overcome these issues, we developed a novel anti-tumor therapeutic EndoCD
fusion protein which linked endostatin (Endo) to cytosine deaminase-uracil
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phosphoribosyl transferase (CD). Endo targets unique tumor endothelial cells to
provide tumor-specific antiangiogenesis activity and also carries CD to the local
tumor area, where it serves nontoxic prodrug 5-fluorocytosine (5-FC) enzymatic
conversion reaction to anti-metabolite chemotherapy drug 5-fluorouracil (5-FU). We
demonstrated that 5-FU concentration was highly increased in tumor sites, resulting
in high level of endothelial cells and tumor cells cytotoxic efficacy. Furthermore,
EndoCD/5-FC therapy decreased tumor growth and colorectal liver metastasis
incident compared with bevacizumab/5-FU treatment in human breast and colorectal
liver metastasis orthotropic animal models. In cardiotoxicity safety profile,
EndoCD/5-FC is a contrast to bevacizumab/5-FU; lower risk of cardiotoxicity
induction or heart function failure was found in EndoCD/5-FC treatment than
bevacizumab/5-FU does in mice. EndoCD/5-FC showed more potent therapeutic
efficacy with high safety profile and provided stronger tumor invasion or metastasis
inhibition than antiangiogenic drugs. Together, EndoCD fusion protein with 5-FC
showed dual tumor targeting activities including antiangiogenesis and tumor local
chemotherapy, and it could serve as an alternative option for antiangiogenic therapy.
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CHAPTER 1: INTRODUCTION

1.1 Tumor angiogenesis
Tumors initially grow as avascular nodules by absorbing nutrient and removing
waste through simple diffusion. However, the growing beyond the size of
approximately 1 mm diameter, the tumors require a delicate network of blood
vessels to supply the nutrient and oxygen and remove waste products (Folkman,
1971). The neovasculation process in tumors is so called “tumor angiogenesis” or “
angiogenesis switch” (Bergers and Benjamin, 2003). Classically, the transition of
vascularization results from the angiogenesis switch driven by hypoxia. Tumors can
produce several angiogenic activators to attract and activate endothelial cells, which
is a critical step to mediate angiogenesis. Activation of endothelial cells initiates the
cell proliferation, which in turn induces sprouting from exiting vessels, migration, and
adhesion of endothelial cells to from a lumen. New formation of vessels under
angiogenesis process continues to provide the necessary nutrients for cancer cells
to grow and survive (Bergers and Benjamin, 2003). Moreover, recent literatures
show that glioblastma cancer stem cell by itself can differentiate to endothelium
phenotype, and the neo-formed vessels contribute to tumor progression and
metastasis (Bautch, 2010; Ricci-Vitiani et al., 2010; Wang et al., 2010b). Tumor
angiogenesis may therefore occur through two distinct mechanisms, which by
attracting endothelial cells to from vessels (classical angiogenesis process), or by
differentiating from cancer stem cells themselves.
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1.2 Antiangiogenesis therapeutic strategy
Classical angiogenesis process involves the interaction between angiogenesis
factors as an inducer and endothelial cells as a responder. This angiogenesis
process could be indirectly inhibited by neutralizing ligands (for example, vascular
endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)); blocking
receptors tyrosine kinase activity (for example, vascular endothelial growth factor
receptors (VEGFR), platelet-derived growth factor receptors (PDGFR)); or directly
suppressed endothelial cell proliferation and migration. Therefore, these can be
classified two kinds of method to inhibit angiogenesis process. One is “direct
antiangiogenesis” and another one is “indirect antiangiogenesis” (Kerbel and
Folkman, 2002). The inhibitors that serve direct antiangiogenesis include endostatin
(O'Reilly et al., 1997), angiostatin (O'Reilly et al., 1994), tumstatin (Sudhakar et al.,
2003), and others (Cao, 2001). Most of them are endogenous proteins to be directly
targeted to endothelial cells and restrain endothelial cell proliferation and migration.
Indirect antiangiogenic inhibitors include VEGF (Kim et al., 1993) or PDGF
monoclonal antibodies; or receptor tyrosine kinase inhibitor (TKI) (Ivy et al., 2009),
which inhibit neovascularization by either neutralizing angiogenesis-inducing ligands
or preventing receptors involved in angiogenesis pathways. Inhibition of tumor
growth through antiangiogenesis therapeutic strategy may present certainly
advantage of safety and low incident of drug resistant, and antiangiogenesis have
potential to inhibit tumor invasion, and metastasis (Folkman, 2006).
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1.3 Antiangiogenic drugs
There are many antiangiogenic targeting molecules tested in the clinical trials
and pre-clinical studies. However, one of well recognized angiogenesis factor is
vascular endothelial growth factor (VEGF), which has been demonstrated to play a
crucial role in regulating tumor angiogenesis (Petrova et al., 1999) and normal
vascular development (Fong et al., 1995; Shalaby et al., 1995). VEGF is secreted by
starving cancer cells and bind to the receptors in endothelial cell to elicit several
endothelial cells response including microvascular permeability (Dvorak et al., 1995),
secretion of matrix-degrading enzymes, endothelial cell proliferation, migration, and
survival (Terman and Stoletov, 2001). Therefore, antiangiogenesis by inhibiting of
VEGF/VEGFR signal pathway was considered a good strategy for anti-tumor
treatment. United states Food and Drugs Administration (FDA), up-to-date, has
approved several antiangiogenic drugs which are shown promising anti-tumor
results in the cancer patients in the clinic (Folkman, 2007). Bevacizumab (Bec or
Avastin) is a monoclonal antibody that neutralizes VEGF to prevent new vascular
formation. Bevacizumab is a first approved antiangiogenic drug in 2004 for
combinational treatment with chemotherapy for metastatic colorectal cancer (Cohen
et al., 2007b; Ratner, 2004) . Continuingly, bevacizumab was approved for treatment
of patients with non-small cell lung cancer (Cohen et al., 2007a), metastatic breast
cancer (Spalding, 2008), galioblastoma (Cohen et al., 2009), and renal cell cancer
(Summers et al., 2010). However, currently FDA recommends removing
bevacizumab from the treatment for metastatic breast cancer patients because
clinical outcome doesn’t show significant tumor inhibition and better patent survival
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(Burstein, 2010). Sorafenib and sunitinib are small molecular inhibitors that can
block not only VEGFR tyrosine kinase activity but also PDGFR activity as well
(Gotink and Verheul, 2010). In July 2011, FDA announces that bevacizumab is
alternative option for some patients who treat in combination with chemotherapy.
Sorafenib was approved by FDA for treatment of patients with renal cancer in 2005
(Eto and Naito, 2006) and hepatocellular carcinoma in 2007 (Flaherty, 2007);
Sunitinib was first antiangiogenic drugs approved for two different cancer types at
same time, renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stoma
tumor (GIST) in 2007 (Rock et al., 2007). So far, three FDA approved antiangiogenic
drugs (Bevacizumab, Sorafenib and Sunitinib) are all belong indirectly strategy to
inhibit vascular growth.

1.4 Antiangiogenic drugs clinical hindrances
Ideal, anti-tumor drugs should have superior therapeutic window, i.e. high
therapeutic efficacy and high safety. Chemotherapy can provide good anti-tumor
activity (Morgan et al., 2004) but low safety because it lacks cancer cell specific
targeting, resulting in frequently severe side effects (Orditura et al., 2004). On the
other hand, antiangiogenic strategy is a quite different anti-tumor strategy from
chemotherapy by blocking oxygen and nutrients supply to the tumors to suppress
tumor growth. Because of this unique therapeutic strategy, it proposed a couple of
advantages. First, it would be less possibility to induce drug resistance because it
targets genetically stable endothelial cell instead of targeting genetically unstable
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tumor cells. Second, it would have less off-targeting issues because tumor
associated endothelial cells are uniquely proliferating which are different from
quiescent normal endothelial cells (Augustin et al., 1994; Denekamp, 1984). In vitro
preclinical data and in vivo animal models indeed provided the experimental results
to support these predictions that antiangiogenic therapy is effective therapeutic
strategy with low incident of drug resistance and without virtual toxicity (Boehm et
al., 1997). Compared to side effects induced by traditional chemotherapy, the toxicity
could be ignored in antiangiogenic treatment. However, accumulating clinical
evidence has changed these principles and shown that antiangiogenic agents still
induce drug resistance (Schmidt, 2009) and side effects (Hasani and Leighl, 2011).

1.4.1 Drug resistance
When cancer patients are treated with antiangiogenic agents, several
mechanisms will respond to the inhibition of tumor vascular formation to avoid it.
Those emerging mechanisms can generalize two models of antiangiogenic drug
resistance, in specially targeting VEGF/VEGFR pathway: one, adaptive resistance;
and the other, intrinsic (pre-existing) non-responsiveness resistance.
For adaptive resistance, tumor cells initially respond to anti-VEGF/VEGFR
therapy and then adapt to treatment by inducing other angiogenic mechanisms to
lead tumor relapse and progression. The induction of tumor vascular formation can
be regulated by redundantly several angiogiogenesis mechanisms which contain at
least four different mechanisms: activation other pro-angiogenic factors from tumor
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cells, tumor-associated fibroblast, or stem cells (Fischer et al., 2007); bone marrowderived progenitor cells recruitment; increasing vessels protection by pericyte
coverage; and enhancement of tumor cell invasion for oxygen and nutrients
requirement (Ebos et al., 2009; Paez-Ribes et al., 2009).
For intrinsic resistance, tumor vascular formation may regulate by multiple
redundant angiogenesis factors which does not respond to antiangiogenesis
monotherapy (Kerbel, 2009). Combination therapy to reduce drug resistance and
further enhance therapeutic efficacy has been proposed; however, adverse effects
cause patients in shorter progression-free survival (Tol et al., 2009).

1.4.2 Side effects
Anti-VEGF/VEGFR antibodies can block or neutralize angiogenesis induced
by VEGF/VEGFR stimulation, and their less tumor specific targeting activity
frequently lead off-target effects. In addition to tumor growth and survival, VEGF
signaling pathway play an important role in normal physiological process to maintain
homeostasis (Verheul and Pinedo, 2007). Example of side effects induced by antiVEGF/VEGFR drug treatment includes hypertension, proteinuria, and impaired
wound healing. In addition to management side effects, antiangiogenic treatment
also induces potential life-threatening complications, gastrointestinal perforation
responds in short-term treatment and cardiac function failure under long-term
treatment (Force et al., 2007; Kramer and Lipp, 2007).
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1.5 The concepts of antiangiogenic therapy potential prevent drug resistance
Multiple clinical trials have demonstrated that antiangiogenic therapy has clinical
benefits, and some of antiangiogenic agents were approved by FDA. However, the
emergence of drug resistant tumors in clinic has largely been unexpected compared
with antiangiogenesis original principles. The potential mechanisms of drug
resistance have been predicted by researchers and clinicians. They suggest some of
possible treatment methods to ameliorate or avoid drug resistance.

1.5.1 Chemotherapy strategy contain antitangiogenic effect
The dose of chemotherapeutic agents is determined based on well
established concept of maximum tolerant dose (MTD) in order to provide the best
antitumor efficacy. However, 'the more frequent is better' or 'less is more' is a
controversial issue. Higher dose is expected more anti-tumor effects but less
survival benefits due to adverse effects in patents (Nieto, 2003; Roche et al., 2003).
On the other hand, low dose of chemotherapy, which is also known as metronomic
therapy, has been found to be able to reduce adverse effects but show
antiangiogenic effects. In such low dose of chemotherapy, the dose sufficient to
inhibit endothelial cells proliferation to from new vascular in tumor microenvironment
but lower than the dose required killing the tumor cells is used (Citron et al., 2003;
Tuma, 2003).
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1.5.2 Combination therapy of antiangiogenic and chemotherapy agents
The anti-tumor efficacy of chemotherapeutic agents also depends on
blood stream. Thus, one potential rationale for the combination of antiangiogenic
agent and chemotherapy is that antiangiogenic therapy can normalize vascular flow,
resulting in increased oxygenation and delivery of chemotherpetic agents (Brown
and Giaccia, 1998). The other potential reason is that VEGF can serve as an antiapoptotic molecule that protects endothelial cells as well as cancer cells from
apoptosis induced by standard treatment. Therefore, it is reasonable to combine
chemotherapy with antiangiogenesis to enhance therapeutic efficacy of both the
cytostatic and cytotoxic effect (Sweeney et al., 2001).

1.5.3 Combination therapy of multiple antiangiogenic agents
In tumor progression process, VEGF is not the only angiogenic factor
secreted by tumor cells. It has been already known that several angiogenic factors
can redundantly regulate tumor angiogenesis. When patients are treated by antiVEGF antibody, the hypoxia will be induced in tumor microenvironment. Not only
tumor cells but also tumor-associated fibroblasts and microphages are stimulated by
hypoxia, and then secret other angiogenic factors than VEGF to rescue hypoxia
condition (Ivy et al., 2009). Therefore, it is not sufficient to inhibit tumor angiogenesis
by monotherapy. Beside of VEGF, there are up to six different angiogenic factors
and several intracellular factors have been recognized to modulate angiogenesis in
different stages of breast cancer cell development (Relf et al., 1997). Thus,
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treatment with multiple antiangiogenic agents may reduce the emergence of drug
resistance risk in clinic.

1.5.4 Combination therapy of antiangiogenic agents and biological
molecular targeting agents
Tumors with epidermal growth factor receptor (EGFR) overexpression/
mutation or human epidermal growth factor receptor-2 (HER-2) overexpression can
be specifically selected for the treatments with the targeting agents that inhibit these
receptor tyrosine kinases such as monoclonal antibodies or small molecule tyrosine
kinase inhibitors. Because VEGF expression can be regulated by the EGFR family
tyrosine kinases in tumors, these targeting agents also reach antiangiogenesis
effects (Bruns et al., 2000; Clarke et al., 2001; Maity et al., 2000). However, clinical
evidence shows that some tumor cells eventually become resistant to anti-EGFR
antibody treatment, resulting in tumor recurrence because of increased VEGF
expression (Viloria-Petit et al., 2001). Therefore, the combination therapy of
antiangiogenic agents and biological molecular targeting therapy may be the
alternative strategy to overcome targeted therapy resistance in some types of
tumors.

1.5.5 Antiangiogenic agents itself as multiple targeting therapy

9

As mention previously, several angiogenic factors can contribute to tumor
progression in different stages. Currently, next-generation antiangiogenic agents that
target multiple molecules have been developed. For example, Sunitinib or sorafenib
as multiple tyrosine kinase inhibitors which can inhibit PDGFR and VEGFR activity.
These agents block multiple molecular targets, resulting in increased antitumor
activity and decreased drug resistant potential at the same time (Teicher, 2010).

1.6 Broad-spectrum angiogenesis inhibitors
Over 100 years of cancer research, many critical signaling pathways involved in
tumor initiation/progression has been identified. Now, it has been believed that
several important signaling pathways can interplay with each other to redundantly
regulate tumor progression. Therefore, even though one important oncogenic
molecule is blocked by anti-tumor therapy, the other similar function molecular will
express to rescue tumor development. Therefore, development of broad-spectrum
angiogenic inhibitors is a new challenge for antiangiogenic agents.

1.6.1 Endostatin
Endostatin is an endogenous angiogenesis inhibitor which is divided from
C-terminal of collagen XVIII to become a 20 kDa fragment molecule. O’reilly and
collogues discovered endostatin in 1997 (O'Reilly et al., 1997) and determined it can
inhibit endothelial cell proliferation, migration by binding to α5β1, αvβ3, and αvβ5
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integrin receptors (Sudhakar et al., 2003). Endostatin contains the broadest
antiangiogenic spectrum activity though downregulation several angiogenesis
pathway (Abdollahi et al., 2004) but induces less toxicity in mice (Zhang et al.,
2010). Under phase I clinic trail, endostatin showed virtually no toxicity and no drug
resistance respond from patients who were received endostatin treatment everyday
over 3 years. However, no significant clinical outcome in multiple endostatin clinical
trials was observed (Herbst et al., 2002; Yang et al., 2006) due to poor anti-tumor
efficacy and short half-life (Fu et al., 2009; Kulke et al., 2006). In China, Wang and
collogues succeed to overcome short half-life issue of endostatin. Endostatin was
approved by the State Food and Drug Administration (SFDA) to use in non-small cell
lung cancer in China (Wang et al., 2005). Although endostatin is not the only one
factor containing broad antiangiogenic spectrum activity, this endogenous
antiangiogenic protein has been tested in clinical trials more than any other proteins
in recently decade.

1.6.2 Endostatin fusion protein
In order to overcome the weakness of endostatin, researchers have
attempted to modify this protein to increase either protein stability and/or anti-tumor
efficacy. It has been shown that Fc domain of IgG is linked to N-terminal of
endostatin to prolong endostatin protein stability and anti-tumor efficacy in
comparison with original endostatin (Lee et al., 2008). An additional metal-chelating
sequence (MGGSHHHHH) was integrated at the N-terminus of endostatin to provide
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additional zinc binding site, and the zinc-binding significantly reduced thermal
induced protein degradation (Jiang et al., 2009). This modified endostatin, which is
named as endostar, is approved for the treatment of non-small cell lung cancer
patients in China. Moreover, endostatin has been fused with HER2 monoclonal
antibody, angiostatin, or antagonist integrin receptor RGD peptide to increase antitumor efficacy and antiangiogenic activity in multiple cancer types including colon
cancer, ovarian, and pancreatic cancer. (Belur et al., 2011; Jing et al., 2011; Shin et
al.; Tysome et al., 2009; Tysome et al., 2011).

1.7 Enzyme-prodrug therapy
Enzyme-prodrug therapy is one of anti-tumor therapeutic strategies which need
to metabolize or transform an inactive prodrug to an effective drug. Example of
Enzyme-prodrug therapy are focused on inhibition of cell proliferation that preferable
kill proliferation cell by blocking cell DNA/RNA synthesis and replication level.
Enzyme-prodrug therapies can provide large amounts of tumor cells killing activity in
short treatment cycles (Frei et al., 1988). However, there are some limitations for
prodrugs in clinical application, including less tumor cell specific targeting activity,
normal tissue off-targeting toxicity, and insufficient drug concentration in tumor sites
by systemic treatment (Denny and Wilson, 1998; Evrard et al., 1999; Springer and
Niculescu-Duvaz, 2000). When the cytotoxic drugs suppress tumor cell growth, they
also kill the normal cell as well, particularly in the proliferating tissues such as bone
marrow. Therefore, development of tumor specific targeting strategies for prodrug
therapy becomes a big challenge in cancer research. After decades of cancer
12

research, researchers have identified several ways to activate prodrugs specifically
in tumor sites, such as gene-directed enzyme prodrug therapy (GDEPT) (Dachs et
al., 2009), virus-directed enzyme prodrug therapy (Grove et al., 1999), and antibodydirected enzyme prodrug therapy (Bagshawe, 2009).
Cytosine deaminase is a yeast enzyme which can catalyze enzymatic
conversion of 5-flucytosine (5-FC) prodrug into chemodrug 5-fluorouracil (5-FU)
(Pandha et al., 1999). Under this metabolism process, the cytosine deaminase
linked with uracil phosphoribosyl transferase (we will refer to this fusion gene as CD)
has been found to be able to enhance the enzymatic conversion compared to
cytosine deaminase alone (Chung-Faye et al., 2001). This fusion strategy has been
well established to enhance therapeutic effects in cancer cells (Erbs et al., 2000;
Ramnaraine et al., 2003). However, systemic treatment with prodrugs induces offtarget effects link to side effects, and general disadvantage of prodrug system is still
tumor targeting difficulty as described above.

1.8 Working model Hypotheses
As we mentioned before, indirect antiangiogenic drugs are more likely to induce
drug resistance than direct ones because their targets are genetically unstable
cancer cells. Recently, it has also been found that glioblastoma cancer stem-like
cells could differentiate to endothelial cells which continue to provide nutrient to
cancer cells and maintain cancer cells growth and survival. Alternatively, the
strategy for antiangiogenesis should specifically target tumor endothelial cells rather
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than cancer cells, and then it would provide greater clinical benefits than targeting
tumor cells (Bautch, 2010). Therefore, it is promising to choose direct antiangiogenic
agents which specifically target genetically more stable endothelial cells (Kerbel and
Folkman, 2002; Kerbel, 1991). However, the direct antiangiogenic agents are mostly
endogenous molecules and have some disadvantages including low protein stability
and low anti-tumor activity. By linking with therapeutic molecules, their weak antitumor activity and protein stability could be improved. In our study, we engineered
endostatin used with CD in order to complement individual weakness and further
provide a good therapeutic window including higher anti-tumor activity as well as low
side effects and emergence of drug resistance. The major concept of this study is
that EndoCD fusion protein has dual-targeting function. Not only does it have the
capabilities of limiting endothelial cell growth (cytostaticity, by endostatin) but also
killing cancer cells (cytotoxicity, by conversion of 5FC to 5FU at the tumor site).
Endostatin is able to specifically target the fusion protein to tumor endothelial cells.
CD is brought to tumor sites by its fusion with Endostatin, and therefore, 5-FC is
converted to cytotoxic 5-FU only at the tumor sites. Therefore, EndoCD/5-FC
provides dual targeting actvites including tumor antiangiogenesis and chemotherapy.
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CHAPTER 2: MATERIAL AND METHOD

2.1 Reagents.
5-fluorouracil was purchased from InvivoGen (San Diego, CA), 5-fluorocytosine
from Sigma (St. Louis, MO), and bevacizumab from the Department of Pharmacy at
MD Anderson Cancer Center.

2.2 Cell Lines.
MDA-MB-231 and murine 4T1 breast adenocarcinoma cell lines were
maintained in Dulbecco’s modified Eagle’s (DMEM)/F12 medium supplemented with
10% fetal bovine serum (FBS). HUVECs were cultured in endothelial cell medium-2
(Cambrex, East Rutherford, NJ). This colon cancer cell line was generated by our
laboratory after several cycles of preselection from an orthotopic colon model that
produced 100% liver metastasis and was maintained by G418 selection.

2.3 Recombinant Protein Purification.
The coding sequence of the human endostatin (Endo) was amplified from
pPICZaA/hE (EntreMed) by polymerase chain reaction and cloned into the pET28
bacterial expression vector (Novagen) to generate pET28Endo. The yeast cytosine
deaminase-uracil phosphoribosyl transferase (CD) was sub-cloned from pORF5Fcy::Fur into pET28 (pET28CD). To generate pET28EndoCD, the fragment
containing CD coding sequence was ligated to the 3’ end of Endo to allow
expression of the fusion protein as a single polypeptide. Recombinant proteins
(Endo, CD, and EndoCD) were expressed from pET28Endo, pET28CD, and

15

pET28EndoCD and purified from a liter of IPTG-induced bacterial culture based on
the procedures previously described (Huang et al., 2001). The pellet was
resuspended in Buffer A (0.1 M Tris-HCl, pH8.0 and 5 mM EDTA, 0.1% sodium
deoxycholate) and incubated at 4C with the addition of lysozyme to a final
concentration of 50µg/ml. The cells were sonicated and centrifuged at 8,000 X g for
10 min. The pellet was washed twice with Buffer A and resuspended in Buffer B
(0.05 M Tris-HCl, pH 8.0, 1% sodium lauroyl sarcosine (SLS), and 1 mM DTT) 4C
overnight. After centrifugation, cleared supernatant was dialyzed sequentially
against the following solution at 4C: Buffer C (0.05 M Tris-HCl, pH 8.0, and 1 mM
DTT), Buffer D (0.05 M Tris-HCl, pH 8.0), and Buffer E (0.05 M Tris-HCl, pH 8.0,
0.01 mM oxidized glutathione, and 1 mM reduced glutathione). A final dialysis step
against 0.05 M Tris-HCl, pH 8.0 was performed to remove glutathione. The
recombinant proteins were determined to be endotoxin free, and protein
concentration was quantitated by using Bio-Rad dye method as described in the
commercial protocol. The proteins were stored in aliquots with 0.05 M Tris-HCl, pH
8.0 buffer in the -80C. The molecular weight of Endo, CD, and EndoCD is 20 kDa,
40 kDa, and 60 kDa, respectively. Therefore, an equimolar ratio (1:2:3) of the
proteins was used for all experiments.

2.4 Cell Viability Assay.
5 X 104 cancer cells MDA-MB-231 were passed in a 96-well plate overnight.
Endo, CD and Endo-CD recombinant proteins with 100 g/ml 5-FC were put into
each well. After 48 hr, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
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bromide) solution at 50 l per well (2 mg/ml; Sigma) was added into the cell culture
and incubated for 2 hours, followed by addition of 100 l of dimethyl sulfoxide
(Sigma) to each well. Absorbance at 570 nm was measured immediately using a
multi-well scanner (Labsystems, Helsinki, Finland).

2.5 Endothelial Tube Assay.
Matrigel (BD Biosciences, San Jose, CA) was added to each well of a 96-well
plate and allowed to polymerize. A suspension of 5  103 HUVEC cells was passed
into a Matrigel-coated well. The cells were treated with Endo, CD or EndoCD, and
the treatment concentration was determined based on their respective molecular
ratios. The cells were incubated for 4-6 hr at 37°C and viewed under a microscope.
Five fields were viewed, and tubes were counted and averaged. All assays were
performed in triplicate.

2.6 Migration Assay.
The inhibitory effect of endostatin on VEGF-induced chemotaxis was tested by
using an 8-m Boyden chamber (Costar, Acton, MA) assay. HUVECs (1 X 104) were
seeded in the upper chamber wells with 2% fetal bovine serum in the EBM medium
(Cambrex, East Rutherford, NJ) and mixed together with Endo, EndoCD, or CD, and
the treatment concentration was determined based on their respective molecular
ratio. EGM2 medium (Cambrex) containing several growth factors were placed in the
lower chamber as a chemo-attractant. The chamber was incubated at 37°C for 24
hr. After the non-migrated cells were discarded and the upper wells were washed
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with PBS, the filters were scraped with a Q-tip, and the cells were fixed in 4%
formaldehyde in PBS and stained with 4',6-diamidino-2-phenylindole (DAPI)
fluorescent dye. Three fields were viewed under a fluorescence microscope, and the
cells were counted and averaged. All assays were performed in triplicate.

2.7 Animal Models.
All animals were maintained in the animal facility and experiments were carried
out under the institutional guidelines of The University of Texas MD Anderson
Cancer Center. For the syngeneic model, BALB/c mice were inoculated (mammary
fat pad) with 1 X 105 4T1 murine breast adenocarcinoma cells. After the tumor
volume reached 3-5 mm in diameter, equamolar amount of proteins (Endo, CD and
EndoCD) were injected via tail vein (Endo 2.5 mg/kg) every other day. One hour
after protein treatment, all groups received 5-FC (500 mg/kg) by intraperitoneal
injection.
For the orthotopic xenograft model, nude mice were inoculated with 3 X 106
MDA-MB-231 human breast cancer cells in the mammary fat pad or 3 X 106 620-L-1
human colon cancer cells in the cecal wall. After tumors were established 7 days
post injection, EndoCD (60 mg/kg, twice per week) or bevacizumab (Avastin, 10
mg/kg, once every two weeks) (Kabbinavar et al., 2003) was intravenously injected,
and 5-FU (15 mg/kg, once per week) (Kabbinavar et al., 2003) or 5-FC (500 mg/kg;
given 1 hr after EndoCD treatment) was administered by intraperitoneal injection.
For practical clinical reasons, the treatment protocols for bevacizumab and 5-FU
were essentially derived from previously established clinical doses and schedules
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(Kabbinavar et al., 2003). Mice which received 10 mg/kg bevacizumab (once every
two weeks, the clinical dose and schedule used in treating breast and colon cancer)
or 60 mg/kg EndoCD (twice per week; protein dosage was based on endostatin
clinical dosage 20 mg/kg and schedule was based on protein stability) via tail vein
injection. Tumor volume was monitored by measuring luciferase signals using IVIS
(In Vivo Imaging System; Xenogen, Alameda, CA). In a reduced-treatment
experiment, the number of treatments given was decreased from 10 to 5. All protein
treatments were given intravenously while chemical drugs were administered by
intraperitoneal injection.

2.8 Immunofluorescence Staining.
Frozen sections (4-m) were fixed in cold 100% acetone for 5 min and then airdried. After immersion in 1X PBS for 15 min, the slides were incubated with rat
monoclonal anti-CD31 antibody (BD Biosciences, San Jose, CA) at room
temperature for 1 hr, rinsed with 1X PBS and then incubated with goat anti-rat
immunoglobulin G conjugated to Texas Red (1:200; Jackson ImmunoResearch
Laboratory, West Grove, PA) in the dark at ambient temperature for 60 min. CD31positive blood vessels were counted in 10–30 fields at 200X magnification in a
blinded fashion.

2.9 In vivo Apoptotic (TUNEL) Assay.
For in vivo apoptotic assay, tumors were fixed in 10% formalin and embedded in
paraffin blocks. Tissue sections were incubated with proteinase K (20 mg/ml in
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10mM Tris-HCl, pH 7.4–8.0, for 15 min at 37oC), permeabilized in 0.1% Triton-X-100
in 0.1% sodium citrate, and then labeled with the TUNEL (deoxynucleotide
transferase-mediated dUTP-biotin nick end labeling) reaction mixture (Promega,
Madison, WI) according to the manufacturer’s protocol. Briefly, biotinylated
nucleotide mix and TdT enzyme were added and incubated at 37oC for 1 hr. The
slides were washed in PBS, blocked in hydrogen peroxide, incubated in streptavidin
horseradish

peroxidase,

developed

in

3,

30-diaminobenzidine,

and

then

counterstained with hematoxylin. The apoptotic cells (brown staining) were counted
under a microscope. In each sample, 5 fields were randomly counted for the
apoptotic cells.

2.10 In vivo BrdU Incorporation Assay.
MDA-MB-231 breast cancer cells were first injected into the mammary fat pad of
nude mice, and when tumors reached 10 mm in diameter, mice were then treated
once only with purified Endo (20 mg/kg), CD (40 mg/kg), EndoCD (60 mg/kg)
proteins plus 500 mg/kg 5-FC, a clinically sufficient dose of 5-FU (15 mg/kg; 1X 5FU), or 10 times the clinically sufficient dose (150 mg/kg; 10X 5-FU). The choice of
20 mg/kg Endo was based on a previous preclinical study(O'Reilly et al., 1997) and
is also within the dosage range tested in the Phase I clinical trial(Herbst et al., 2002)
(15-600 mg/m2 in human is equivalent to 4.8-194.4 mg/kg in mouse (Freireich et al.,
1966)). BrdU was intraperitoneally injected at 1 mg/kg 18 hr before tumors were
harvested. Tumor sections were stained by BrdU antibody as previously described

20

(Mizoguchi et al., 2009), and the percentage of BrdU-positive cells was calculated by
Automated Cellular Imaging System (ACIS III, Dako).

2.11 LC/MS/MS.
The HILIC and mass spectrometry condition was modified based on the
previous studies (Kosovec et al., 2008; Pisano et al., 2005). First, tumor-bearing
mice were administered with 500 mg/kg 5-FC, 10X-5-FU, or 60 mg/kg EndoCD plus
500 mg/kg 5-FC. Tumor samples were harvested after 5-FU or EndoCD/5-FC
treatment for 2 hours. Depending upon the weight of the tissues to be processed, a
100 mg/mL tissue suspension in methanol containing 100 ng/mL of 5-Bromouracil
(5-BrU, Sigma) was prepared as an internal standard; calculate the tissue volume as
1 µL per mg of tissue weight. Tissue weight >200 mg prepare 100 mg/mL
suspension; tissue weight <200 mg prepare 50 mg/mL suspension. (For example:
250 mg tumor tissue = 250 µL volume; to prepare a 100 mg/mL suspension in
methanol add 2250 µL of methanol + 100 ng/mL 5-BrU, the final volume upon
homogenization will be 2500 µL at 100 mg/mL concentration). Tumor was
homogenized by Mistral Ultrasonic tissue homogenizer and samples centrifuged for
5 min at maximum speed at 4˚C to pellet any solid material. The cleared supernatant
was then transferred into a sample vial for analysis by LC/MS/MS.

2.12 Small Animal MRI.
Cardiac MRI was carried out as previously described (Wang et al., 2010a).
Mice were anesthetized with isoflurane in a circulatory heating stage throughout the
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procedure. The dose was adjusted to maintain a respiratory rate between 20 and 50
breaths per minute. Magnetic resonance imaging of the heart was conducted with a
Bruker 7.0T scanner located in Small Animal Imaging Facility at the University of
Texas MD Anderson Cancer Center. Image streams of serial short axis sections
covering the whole heart (1.0 mm in thickness) were obtained with IG-Flash-cine
sequences. End-systolic volume (ESV) and end-diastolic volume (EDV) of each
section were manually segmented, and left ventricular ejection fraction was
calculated by the following formula: LVEF = (ΣEDV-ΣESV)/ΣEDV.

2.13 Hydroxyproline assay.
This assay was modified from a previously described protocol (Kliment et al.,
2009; Woessner, 1961). Hearts harvested from treated and untreated mice (13-18
mg) were hydrolyzed in 6N HCl at 50°C overnight in a glass tube and neutralized
with NaOH and vacuum dried at 40°C. The pellet was resuspended in 1 ml of 5 mM
HCl. A 1:10 dilution of each samples in a total volume of 200 µl was mixed with 100
µl of chloramine T solution (2 ml H2O, 0.14 g chloramine-T, 8ml hydroxyproline
assay buffer (11.4 g sodium acetate anhydrous, 7.5 g trisodium citrate dihydrate,
and 77 ml isopropanol; final volume was 200 ml with H2O, pH 6.0, and 1.25 ml of
Erlich’s reagent containing 6 g p-dimethylaminobenzaldehyde, 18 ml 60%
perchlorate, and 78 ml isopropanol). The samples were incubated at 55°C for 20 min
and read at OD570 nm. Trans-4-hydroxy-L-proline was used as standard curve to
determine hydroxyproline concentration. The control group was set as basal level 1.
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2.14 Masson’s trichrome staining.
Masson’s trichrome staining solution was purchased from Sigma. Tissue
section was deparaffinized, rehydrated and put in Bouin's Solution at room
temperature overnight. The samples were washed in running tap water for 5 min to
remove the yellow color from the section, stained in Weigert's Iron Hematoxylin
Solution for 5 min, washed again in running tap water for 5 min, and then stained in
Biebrich Scarlet-Acid Fuchsin for 5 min. The slides were then placed in
phosphomolybdic/ phosphotungstic acid solution for 10 min, transferred to Aniline
blue for 5 min, placed in 1% acetic acid solution for 3 min, and then rinsed in distilled
water. Finally, the section was washed with 1% acetic acid for 1 minute and rinsed
in distilled water.
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CHAPTER 3: ENDOCD FUSION PROTEIN PURIFICATION

In our previously study, we used gene therapy based strategy to determine antitumor activity and antiangiogenic function of EndoCD (Ou-Yang et al., 2006).
Although the technology of gene therapy is conceptually encouraging, it requires
improvements in delivery methods to be efficiently used in clinical settings and to
enhance its therapeutic effectiveness. The major concerns of gene therapy include
delivery difficulties, low transfection efficiency, and unpredictable dose response.
However, the technology for using protein therapy (e.g., antibodies) has been well
established over the past decade. It has advanced to the extent that targeting
delivery and dose responsiveness are all well controlled. Thus, the FDA has
approved multiple antibodies for cancer therapy, and protein therapy has now
become one of the important strategies in cancer treatment. Therefore, we expect
that EndoCD fusion protein therapy will overcome deficiency of gene therapy and
provide a new strategy for targeting angiogenesis and targeting chemotherapy to
increase anti-tumor activity and reduce side effects.

3.1 Construction of EndoCD protein expression
To obtain EndoCD fusion protein, we first constructed human endostatin (Endo)
or yeast cytosine deaminase-uracil phophoribosyl transferase (CD) protein
expression plasmid (Figure 1A). Each Open Reading Frame (ORF) was subcloned
into pET28 protein expression vector. We also subcloned both Endo and CD into a
single pET28 vector to link Endo DNA sequence with CD DNA sequence (Figure
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1B). Then, we purified each protein as described in Materials and Methods. For
further experiments, we need to adjust each protein concentration to become
equimolar. The approximately 1:2:3 ratios was based on 20 kDa of Endo, 40 kDa of
CD, and 60 kDa of EndoCD protein molecular weight and would perform in the all
experiments (Fig. 2).
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Figure 1. Construction of Endo, CD, and EndoCD protein expression vector.

(A) Vector map of the Endo, CD, and EndoCD fusion protein. EndoCD was clone
into the pET28 vector (Novagen) and expressed in Escherichia coli (BL21) with
an N-terminal histidine tag.

(B) Amino acid sequence of EndoCD fusion protein. Endostatin (red), CD (blue).
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Figure. 1
A.

B.
MHSHRDFQPVLHLVALNSPLSGGMRGIRGADFQCFQQARAVGLAGTFRAFLSSRLQDLYSIVRRA
DRAAVPIVNLKDELLFPSWEALFSGSEGPLKPGARIFSFDGKDVLRHPTWPQKSVWHGSDPNGRR
LTESYCETWRTEAPSATGQASSLLGGRLLGQSAASCHHAYIVLCIENSFMTASKEFVTGGMASKW
DQKGMDIAYEEAALGYKEGGVPIGGCLINNKDGSVLGRGHNMRFQKGSATLHGEISTLENCGRLE
GKVYKDTTLYTTLSPCDMCTGAIIMYGIPRCVVGENVNFKSKGEKYLQTRGHEVVVVDDERCKKIM
KQFIDERPQDWFEDIGEMNPLFFLASPFLYLTYLIYYPNKGSFVSKPRNLQKMSSEPFKNVYLLPQT
NQLLGLYTIIRNKNTTRPDFIFYSDRIIRLLVEEGLNHLPVQKQIVETDTNENFEGVSFMGKICGVSIVR
AGESMEQGLRDCCRSVRIGKILIQRDEETALPKLFYEKLPEDISERYVFLLDPMLATGGSAIMATEVL
IKRGVKPERIYFLNLICSKEGIEKYHAAFPEVRIVTGALDRGLDENKYLVPGLGDFGDRYYCV#
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Figure 2. Endo, CD, EndoCD protein purification

(A) SDS-PAGE analysis of the purified Endo, CD, and EndoCD protein.
Molecular weights of Endo, CD, and EndoCD are 20, 40, and 60 kDa,
respectively.
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Figure 2.

A.
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CHAPTER 4: INVESTIGATION OF ENDOCD FUSION PROTEIN BIOLOGICAL
FUNCTION

4.1 To study EndoCD antiangiogenic function and cell killing activity in vitro
To characterize the biological activities of EndoCD, we purified the His-tagged
recombinant proteins by using bacteria protein expression system. We then tested
the antiangiogenesis activity of purified Endo and EndoCD by tube formation and
migration assays using human umbilical vein endothelial cells (HUVEC). As shown
in Figure 3, inhibition of angiogenesis by EndoCD was similar to that of Endo as both
significantly decreased tube formation (Figure 3, upper panels) and the number of
migrated cells (Figure 3, lower panels) compared with control (mock) or CD
treatment. Next, we examined CD activity by measuring the enzymatic conversion of
the prodrug 5-FC to cytotoxic 5-FU activity by using a cell viability assay in different
cancer cell lines including 4T1 mouse mammary carcinoma; panO2 mouse
pancreatic adenocarcinoma; MDA-MB-231, MDA-MB-468, and MCF7 human breast
cancer cells; BE3, BIC-1, and SKG-4 human esophageal cancer cells lines (Figure
4A-C). As shown in Figure 4, EndoCD evidently suppressed cell viability nearly as
effectively as CD alone, suggesting the fusion protein maintains the 5-FC prodrug
converting enzyme activity.
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Figure 3. Antiangiogenic activites of EndoCD protein in vitro.

Human Umbilical Vein Endothelial Cell (HUVEC) was treated with 2.5 M Endo, CD,
or EndoCD. Upper panels, inhibition of HUVEC tube formation by EndoCD was
similar to that of Endo. Tube formation was counted in three randomly selected
areas. Lower panels, HUVEC migration was blocked by EndoCD under VEGFattracted condition.
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Figure 3.
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Figure 4. Cancer cell killing activities of EndoCD/5-FC protein in vitro.

Cancer cells lines that were treated with 100 g/ml of 5-FC and various
concentrations of Endo, CD, or EndoCD. The cell viability of 5-FC alone group was
set as 100%. , Endo/5-FC; , CD/5-FC; , EndoCD/5-FC.
(A) Mouse 4T1 mammary carcinoma and panO2 pancreatic adenocarcinoma;
(B) Human MDA-MB-231, MDA-MB-468, and MCF7 breast cancer cell lines;
(C) Human BE3, BIC-1, and SKG-4 esophageal cancer cell lines
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Figure 4A.
4T1

panO2
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Figure 4B.

MBA-MB-231

MBA-MB-468

MCF7
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Figure 4C.

BE3

BIC1

SKGT-4
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4.2 To investigate EndoCD/5-FC biological activities in vivo
4.2.1 To investigate the anti-tumor efficacy of EndoCD/5-FC in vivo
We tested EndoCD/5-FC antitumor activity in vivo in a syngeneic
mammary tumor model in which 4T1 breast cancer cells were injected into the
mammary fat pad of BALB/c mice. An equamolar of each protein (2.5 mg/kg of
Endo, 5 mg/kg of CD or 7.5 mg/kg of EndoCD) was administered into the tail vein of
mice every other day (marked by arrows) for a total of 10 treatments, with 500 mg/kg
5-FC (Chung-Faye et al., 2001) injection given 1 hr after protein treatment. The
EndoCD/5FC-treated mice showed more potent tumor suppression (Figure 5A) and
prolonged the overall mean survival rate (Figure 5B) compared with Endo/5-FC- or
CD/5-FC-treated ones. These results indicate that the EndoCD fusion protein inhibits
tumor growth more effectively than the two proteins alone.

4.2.2 To investigate the biological function of EndoCD/5-FC-induced antitumor and antiangiogenic activities in vivo
The tumor samples were harvested from the protein-treated mice to
analyze angiogenesis suppression as well as cancer cell death caused by the
protein therapy. Tumor tissues were subjected to immunofluorescence staining with
CD31 (a marker for endothelial cells) antibody and terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay to characterize program cell
death. The results showed that EndoCD/5-FC decrease tumor vascular density and
cause endothelial and cancer cell apoptosis more significantly than Endo/5-FC and
CD/5-FC alone. We further merged signals from blood vessels and apoptosis by
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double staining in all protein-treated tumor samples. One important finding, which
was specially observed in the EndoCD/5-FC treatment tumor samples, is the
majority of apoptotic signals (green color) surrounded and existed in endothelial cells
(red color) (TUNEL/CD31 panel and inset, Figure 6). These phenomena indicate that
apoptosis was ongoing in tumor endothelial cells treated with EndoCD/5-FC.
Furthermore, apoptosis signals around the endothelial cells suggest that tumor cell
also underwent program cell death process in EndoCD/5-FC treated tumor samples
but not in other protein treatment samples. These results suggest that the specific
cytotoxic activity observed in EndoCD/5-FC treated mice may come from increased
5-FU local concentration.
On the other hand, we also investigate the effects of EndoCD/5-FC protein
on cancer cell proliferation. We established orthotopic human breast cancer animal
model and treated them with the fusion protein with the 5-FC or 5-FU under clinical
condition. Then, we further determined the effects of fusion proteins on cell
proliferation by in vivo BrdU incorporation analysis. The results indicate that the cells
in EndoCD/5-FC-treated tumor samples exhibited less cell proliferation activity than
the cells from tumor samples treated with other protein/prodrug combinations (Figure
7A). This cell proliferation suppression activity of EndoCD/5-FC is even 10 times
more potent than 5-FU treatment (Figure 7B), which encouraged us to measure 5FU concentration at local tumor area.

4.2.3 To quantify 5-FU concentration in tumor
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In order to further verify whether induction of cancer cell apoptosis and
inhibition of cancer cell proliferation are indeed caused by high concentration of 5FU, we further determined 5-FU local concentration by liquid chromatography-mass
spectrometry (LC/MS/MS) in tumors. According to LC/MS/MS analysis, 5-FU
concentration from EndoCD/5-FC-treated tumors was about 7 times higher than that
detected from the 10X 5-FU-treated tumors (Figure 8). Together with those in vivo
function assays, we conclude that EndoCD/5-FC possesses ability to decrease
density of tumor blood vessels and accumulate 5-FU concentration in tumor to
induce apoptosis in both tumor and tumor endothelial cells.
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Figure 5. EndoCD/5-FC anti-tumor activity in breast cancer orthotopic animal
model

(A) BALB/c mice were injected with 4T1 cells into mammary fat pad. Equimolar of
each protein was injected intravenously and all mice were given 5-FC by
intraperitoneal injection 1 hr after protein treatment. Arrow marker represents protein
treatment times. EndoCD/5-FC had the best therapeutic efficacy in suppressing
tumor growth and prolonged the overall mean survival of mice (B).
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Figure 5.
A. 4T1

B
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Figure 6. Biological activity by EndoCD/5-FC in tumor microenvironment.

Immunofluorescence staining of tumor tissues from mice treated with the indicated
proteins and 5-FC combination (from Figure 5). Blood vessel was stained with
vascular marker CD31 antibody (red) and apoptosis signal was detected by TUNEL
assay staining (green). EndoCD/5-FC induced tumor vascular density reduction and
endothelial and tumor cell apoptosis. Represent imaging is shown in left and
quantification of each signal is shown in right.
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Figure 6.
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Figure 7. Inhibition tumor cell proliferation by EndoCD/5-FC

(A) Tumor samples were labeled with BrdU (brown) antibody.
(B) Quantification of BrdU signals. EndoCD/5-FC has more potent to inhibit cancer
cell proliferation than with 10X 5-FU.
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Figure 7.
A.

B.
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Figure 8. Increased 5-FU concentration by EndoCD/5-FC in tumor
microenvironment.

5-FU concentration was detected by LC/MS/MS in tumor. Mice injected 5-FC, 10X-5FU via intraperitoneal injection, or EndoCD/5-FC via intravenous injection.
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Figure 8.
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CHAPTER 5: INVESTIGATION OF ENDOCD PROTEIN STABILITY
To analyze the protein stability, we mixed an equimolar amount of each protein
(Endo, CD, and EndoCD) with mice serum and incubated at 37 degree for the
number of days. The samples were then subjected to western blotting and
hybridized by anti-his-tag antibody. Quantification result shows that the half-life of
Endo protein is less than one day, which consistent with reports from previous
clinical (Eder et al., 2002). However, the EndoCD fusion protein has much longer
half-life, which is about three days in the presence of mice serum (Figure 9).
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Figure 9. The protein stability of EndoCD fusion protein.

The stability of the EndoCD fusion protein is longer than Endo. (a) 12.5 M of each
Endo, CD, or EndoCD were incubated in mice serum, and at the indicated time
points, protein samples were harvested and analyzed by immunoblotting. (b) Protein
bands were quantified and normalized to the day 0. , Endo; , CD; , EndoCD.
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Figure 9.
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CHAPTER 6: INVESTIGATION OF ENDOCD/5FC TOXICITY
To studies the acute toxicity of EndoCD fusion protein, mice were given 60
mg/kg EndoCD by intravenous injection and then 500 mg/kg 5-FC intraperitoneally
injected 1 hr after protein treatment. Mice blood were collected from orbital sinus
every

other

day

for

one

week,

and

liver

functional

markers

aspartate

aminotransferase (AST) and alanine aminotransferase (ALT), as well as kidney
function markers blood urea nitrogen (BUN) and creatinine in mice blood were
detected. The analysis results indicate that all organ functional markers of liver and
kidney (AST, ALT, BUN and creatinine) in EndoCD/5-FC-treated mice were in the
normal range (Khatri et al., 2006) (Figure 10). Moreover, there were no sick signs
found in EndoCD/5-FC treatment group. For example, no mice died more than two
months, nor exhibited less appetite, less activity, and hair loss (data no shown).
Together, the results indicate that EndoCD/5-FC would not have any acute toxicity
nor induce anylife-threaten side effects in mice.
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Figure 10. Acute Toxicity Assay of Endo, CD, and EndoCD fusion protein.

EndoCD/5-FC has virtually no toxicity in mice. 20 mg/kg of Endo, 40 mg/kg of CD, or
60 mg/kg of EndoCD was given to mice by intravenous injection, and all mice were
injected with 500 mg/kg of 5-FC intraperitoneally 1 hr after the protein injection. Mice
blood were then collected from orbital sinus every other day for one week, and liver
and kidney function markers in the blood were determined. AST (A) and ALT (B)
represent liver function; creatinine (C) and BUN (D) represent kidney function. The
red line indicates the normal value. AST, aspartate aminotransferase; ALT, alanine
aminotransferase; BUN, blood urea nitrogen.
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Figure 10.
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CHAPTER 7: ANTI-TUMOR ACTIVITY COMPARISON BETWEEN ENDOCD/5-FC
AND BEC/5-FU
To demonstrate EndoCD/5-FC would be a novel anti-tumor drug in clinic, we
should compare therapeutic efficacy of EndoCD/5-FC and current clinical drugs.
Based on biological function, Endo provide antiangiogenesis activity while cancer
cell killing effects mostly come from 5-FU that is converted from 5-FC by CD. The
mechanism of anti-tumor function of EndoCD/5-FC is similar with bec/5-FU which is
used in several cancer types including metastatic colorectal cancer, non-small cell
lung cancer (NSCLC), and breast cancer.
To compare the therapeutic efficacy of EndoCD/5-FC and bec/5-FU, we
performed two orthotopic tumor models including human breast cancer (MDA-MB231) and human liver metastasis colorectal cancer (620-L-1). SW620 is highly liver
metastasis colon cancer cell line which was generated by several times retransplantation liver metastatic cancer cell in colon. 620-L-1 was developed by our
laboratory and stably expresses luciferase protein for in vivo life image detection.
Breast cancer cells and colon cancer cells were injected into mammary fat pad and
cecal wall of colon, respectively. One week after tumor cell injection, EndoCD/5-FC
or bec/5-FU was injected into the mice at equivalent clinical dose and treatment
schedules. The results shows that EndoCD/5-FC provided significantly better antitumor activity than bevacizumab or 5-FU alone (Figure 11A and 12A) and also
prolonged overall mean survival rate than bev/5-FU (p=0.004) in the colon cancer
model (Figure 12B). However, EndoCD/5-FC showed a similar therapeutic efficacy
to bev/5-FU under this treatment schedules (Figure 11A and 12A).
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To compare the therapeutic efficacy of EndoCD/5FC and bev/5-FU, we
reduced total drug treatments which from 10 times treatment reduce to 5 times
treatment and results shows that EndoCD/5-FC had better tumor suppression
activity than bev/5-FU in the MDA-MB-231 breast cancer mouse model (Figure 11B)
and the metastatic colon cancer mouse model (Figure 12C) when the tumor sizes
were majored on tumor inoculation Day 42 and Day 35, respectively.
As we mentioned in Chapter 1, anti-VEGF/VEGFR drug treatment could
suppress tumor angiogenesis and tumor growth; however, it has recently been
suggested that tumor cells escaped from cell death induced by these therapies may
become refractory tumors with high invasive and metastatic properties (Loges et al.,
2009). To further determine whether EndoCD/5-FC therapy also has this clinical
weakness, we used 620-L-1 liver metastasis colorectal cancer cells as an analysis
model. To monitor cancer cell growth and indicate metastatic tumors, 620-L-1
cancer cells were trasnfected to stably express luciferase protein, which can be
tracked by IVIS-100 live image system. On 35 days after tumor inoculation, mice
treated with EndoCD/5-FC did not show significant liver metastasis, while the
significant liver metastasis was observed in the mice treated with bev/5-FU (Figure
13). Taken together (Figure 11, 12, and 13), these results suggest that EndoCD/5FC has potent therapeutic activity to control tumor growth and survival as well as
metastasis.
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Figure 11. Anti-tumor activity comparison of EndoCD/5-FC and bev/5-FU in an
orthotopic human breast cancer mouse model.

(A) Mice bearing 231 breast tumors were treated with the indicated drug
combination, and growth of tumor volumes were monitored. EndoCD/5-FC showed
significantly better anti-tumor activity than bevacizumab or 5-FU alone. However,
EndoCD/5-FC showed a similar therapeutic efficacy to bev/5-FU under this
treatment schedules. Arrows represent each protein treatment.
(B) Reduced total drug treatments and EndoCD/5-FC had tumor suppression activity
better than bev/5-FU in MDA-MB-231 breast cancer mouse model on tumor
inoculation Day 42. (For detail schedule of reduced treatments, please refer to
material and method.)
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Figure 11.
A. MDA-MB-231

B. MDA-MB-231
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Figure 12. Anti-tumor activity comparison between EndoCD/5-FC and bev/5-FU
in an orthotopic human liver metastasis colorectal cancer mouse model.

(A)EndoCD/5-FC shows significantly better anti-tumor activity than bevacizumab or
5-FU alone and also prolong mice overall mean survival rate than bev/5-FU
(p=0.004) in colon cancer model (B). However, EndoCD/5-FC did not show a
significantly better therapeutic efficacy than bev/5-FU under this treatment
schedules.
(C) Reduced total drug treatments and EndoCD/5-FC had tumor suppression activity
better than bev/5-FU on tumor inoculation Day 35. Arrows represent each protein
treatment. (For detail schedule of reduced treatments, please refer to material and
method.)
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Figure 12.
A. 620-L-1

B. 620-L-1

C.620-L-1
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Figure 13. Liver metastasis comparison between EndoCD/5-FC and bev/5-FU
in an orthotopic human liver metastasis colorectal cancer mouse model.

Mice bearing 620-L-1 colon cancer expressing luciferase were treated by EndoCD/5FC or bev/5-FU. Tumor metastasis signal was tracked by IVIS-100 image on Day 35
after inoculation. The result shows EndoCD/5-FC treatment did not increase liver
metastasis compared with bev/5-FU treatment group.
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Figure 13.
620-L-1
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CHAPTER 8: COMPARISON OF CARDIOTOXICITY BETWEEN ENDOCD/5-FC
AND BEC/5-FU
It has been known that bevacizumab can cause 1.7 to 3% left ventricular
dysfunction incidence, and 5-FU is also well studied to induce ischemic
complications in cancer patients (Yeh and Bickford, 2009). To determine the
cardiotoxicity effects of those drugs including EndoCD/5-FC and bev/5-FU, we
harvested serums from drugs-treated mice (from figures 11 and 12) to further detect
troponin I, which is a biological marker for damage of cardiomyocyte. Troponin I
serum level was dramatically increased in bev- and bev/5-FU-treated breast cancer
mice model. On the other hand, mice treated with bev/5-FU are the only group
showed high level of troponin I in colon cancer model (Figure 14). These results
suggest bev/5-FU treatment may cause cadiomyocyte damage but EndoCD/5-FC
may not.
To further examine whether EndoCD/5-FC protein treatment affects cardiac
function, we used small animal MRI to analyze end-diastolic volume (EDV) and endsystolic volume (ESV) that allowed us to calculate the left ventricular ejection fraction
(LVEF; LVEF = (ΣEDV-ΣESV)/ ΣEDV) (Wang et al., 2010a) of mice before
(pretreatment basal level) and after treatment with bev/5FU or EndoCD/5FC.
Representative EDV and ESV images are shown in upper panel of figure 15 and
LEVF amounts are shown in lower panel of figure 15. LEVF was significantly
decreased in bev/5FU-treated mice in post three-month treatment. On the other
hand, LEVF was only slightly changed in EndoCD/5FC-treated mice even after six-
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month treatment. Therefore, EndoCD/5-FC protein therapy may provide great
advantage because of minimal cardiac impact.
To study the effect of EndoCD/5-FC and bev/5-FU on heart tissue, we
analyzed the incidence of cardiac fibrosis which has abnormal collagen
accumulation. Collagen amounts in heart tissues can be determined by indirectly
detecting hydroxyproline or direct collagen trichrome staining. The heart tissues
were collected from mice used in figure 15, and we found that higher hydroxyproline
amount (Figure 16A) and collagen accumulation (blue color, Figure 16B) in heart
from bec/5-FU-treated mice than hearts from the control mice and EndoCD/5-FCtreated mice.
One of critical VEGF biological function is maintain myocardial angiogenesis;
and it has been demonstrated that ischemic cardiomyopathy would be induced by
loss of VEGF in mice (Carmeliet et al., 1999). To exam the effects of EndoCD/5-FC
and bev/5-FU on mice myocardial angiogenesis, we measured serum VEGF levels
and also determined coronal vessels density by staining with vascular marker CD 31
antibody. Then, we found that circulating VEGF levels significantly reduced in mice
treated bev/5-FU but not in one treated with EndoCD/5FC (Figure 17). Moreover, CD
31 signals, which indicate coronal vessel density, were also decreased in heart
tissues of mice treated bev/5-FU but not in one treated with EndoCD/5FC (Figure
18). Together, these results indicate that bev/5-FU treatment would potentially
induce cardiomyopathy and/or cardiac function failure compared to EndoCD/5-FC
treatment in cancer patients.
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Figure 14. Cardiotoxicity Assay by detecting troponin I level.

Drug-treated mouse serum were collected from two orthotopic mice tumor model
including human breast cancer model (MDA-MB-231) and human liver metastasis
colorectal cancer model (620-L-1) to detect circulating troponin I level by ELISA.
EndoCD/5-FC treatment group did not induce cardiotoxicity in both mice tumor
therapy model. Bec, bevacizumab

(A) High troponin I level induced by bec or bec/5-FU treatment group in breast
cancer model, indicating that Bec and bec/5-FU treatment could cause mice
cardiacmyocyte damage.
(B) Cardiactoxicity was observed only in bec/5-FU treatment mice in human liver
metastasis colorectal cancer model.
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Figure 14.
A. MDA-MB-231

B. 620-L-1
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Figure 15. Cardiac function detection by magnetic resonance imaging (MRI) in
drugs-treated mice

Upper panel is representative image of EDV (end of diastolic volume) and ESV (end
of stoic volume).
Left ventricular ejection fraction (LVEF) was calculated by (ΣEDV-ΣESV)/ ΣEDV
from each treatment mice and shown in lower panel. Before drugs treatment, LVEF
value was set as mice normal value. LVEF value was significantly reduced in bev/5FU treatment group and there was no significant change of LVEF value in
EndoCD/5-FC treatment group after three- and six- month treatment. NS, no
significance. (For detail schedule of reduced treatments, please refer to material and
method.)
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Figure 15.
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Figure 16. Cadiac fibrosis detection in EndoCD/5-FC and bec/5-FU treatment
mice heart.

(A)Hydroxyproline assay.
The hearts were harvested from mice treated with EndoCD/5-FC or bec/5-FU. We
also collected the same age of mice heart as a normal control. The detection amount
was normalized with the weight of heart tissue. The high proline hydroxylation was
detected in the bev/5-FU treatment group, which is significantly higher than control
mice. In contrast, there was no significant difference in proline hydroxylation
between EndoCD/5-FC group and control mice. NS, no significance.

(B) Trichrome staining.
Direct method shows fibrosis phenomena in mice heart. The presence of fibrosis is
shown in blue by trichrome staining of heart histological section. Similar results as
(A) are shown.
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Figure 16.
A.Hydroxyproline assay.

B. Trichrome staining
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Figure 17. Circulating VEGF level comparison in EndoCD/5-FC and bec/5-FU
treatment mice

Circulating VEGF level was lower in bev/5-FU-treated mice than control mice and
there were no significantly changes in EndoCD/5-FC-treated mice compared with
control mice. NS, no significance
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Figure 17.
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Figure 18. Coronal vessels density comparison in EndoCD/5-FC and bec/5-FU
treatment mice

Upper panels are representative images of coronal vascular density hybridizing by
CD31 antibody (red) in mice heart tissue.
Lower panel shows that coronal vascular density was significantly decreased in
bev/5-FU treatment mice compared to control mice but not in EndoCD/5-FC-treated
group. NS, no significance
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Figure 18.
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CHAPTER 9: SUMMARY OF CHAPTER 3 TO 8 AND DISCUSSION

Antiangiogenesis, the novel anti-tumor concept by Judah Folkman, has
become reality during over last three decades and been applied in clinic. Inhibition
tumor growth by anti-VEGF/VEGFR monoclonal antibodies became a first approved
antiangiogenic modality in clinic. Although anti-tumor efficacy was fully tested in
preclinical studies, accumulating clinical reports have shown that these drugs have
cytostatic function without curative potent and further induced tumor recurrence,
tumor invasion and metastasis (Loges et al., 2009). Although targeting therapy
provides predictable safety profile, systemic treatment interrupts normal organ
homeostasis to induce side effects (Verheul and Pinedo, 2007). Therefore,
development of the strategies to enhance therapeutic efficacy and targeting
specificity under center principle of Judah Folkman will become a new challenge in
next decade.
In this study, we set up this challenge as a goal. Namely, we have attempted
to develop a novel antiangiogenic drug which provides high therapeutic efficacy and
decreases incident of tumor recurrence and the risk of tumor invasion and
metastasis. Moreover, to provide the high efficacy, we also tried to increase
targeting specificity to prevent off-target side effect and increase safety. Then, we
finally developed a novel fusion protein EndoCD. Endostatin is broad-spectrum
antiangiogenesis protein which can specifically target tumor vascular system
(Avraamides et al., 2008). In addition, the fusion protein can increase 5-FU
concentration, which is converted from 5-FC by CD, in the tumor microenvironment.
Thus, EndoCD/5-FC offers not only antiangiogenesis by tumor vascular targeting but
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also tumor targeting chemotherapy. Dual targeting effect shown here will provide
curative benefits to cancer patients.
Clinical antiangiogenic drugs belong to indirect antiangiogenesis agents that
selectively target VEGF pathway. Although, VEGF pathway is important for tumor
angiogenesis, it is also known essential for normal physiological maintenance
(Verheul and Pinedo, 2007). Indirect antiangiogenesis agents also block VEGF
function in normal organ, and it perhaps causes side effects. In the principle of
EndoCD fusion protein, it is directly targeted to uniquely proliferating endothelial cell
in tumor sites, and thus it would have decreased off-target potential (Kerbel, 1991).
Moreover, by carrying chemotherapeutic drugs to tumor area, EndoCD enhances
cytostatic effect at the same time. In order to prove the concept, we purified EndoCD
fusion protein from bacteria expression system and determine antoangiogenic and
cell killing activities in vitro and in vivo. EndoCD/5-FC induced endothelial cells and
tumor cells apoptosis and inhibited tumor cell proliferation, and these anti-tumor
activities further reduced tumor cell invasion and metastasis. We also demonstrated
that EndoCD/5-FC fusion protein has dual targeting tumor antiangiogenic and tumor
local chemotherapeutic activities. Together, EndoCD is expected to be able to
decrease potential tumor recurrence and tumor metastasis.
In the present study, we also compared EndoCD/5-FC anti-tumor activity and
safety with a clinical antiangiogenic drug, bevacizumab and 5-FU combination.
EndoCD/5-FC showed better anti-tumor and metastasis inhibition activities than
bec/5-FU. In the safety profile, EndoCD/5-FC provide virtually no toxicity, especially
cardiotoxicity and cadiac function failure, while bec/5-FU exhibited these toxicities.
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Therefore, our studies demonstrated that EndoCD/5-FC may resolve the weakness
of antiangiogenic and chemotherapeutic drugs and reveal a novel potential of
antiangiogenic modality in clinic.
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CHAPTER 10 FUTURE DIRECTIONS
10.1 Improvement of currently protein expression system
In our current protein purification system, when EndoCD fusion protein was
expressed in E. coli, the majority of protein become aggregated and found in
inclusion body of bacteria. Therefore, we first purified the inclusion body to get high
purity of EndoCD protein, and then EndoCD was denatured and refolded though
dialysis procedures. During dialysis procedure, EndoCD structure may be refolded
from linear structure to different stages of tertiary structure. The quality of protein in
each purification batches may vary due to dialysis procedure.. Therefore, we need to
improve or modify currently protein expression system for future clinical application.

10.1.1 To improve protein solubility in different protein expression.
To improve protein solubility, we will test different approaches in our
currently expression system including different expression vectors, different
induction temperature, and modification of the linker. In figure 19A modification
strategy map, we can either change linker or use different tag to test in different
induction temperature. In this expression vector, high solubility of EndoCD protein
can be induced in room temperature (23 ºC) or 4 ºC degree (Figure 19B). We will
further purify soluble protein in large scale E. coli expression system.
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Figure 19. Solubility improvement of EndoCD protein in E. coli system

(A) The strategy map of protein expression map.

(B) EndoFlexCD protein (red color arrow) induction in different temperature. RT,
room temperature; sup, soluble protein; pet, insoluble protein
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Figure 19.
A.

B.
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10.2 To test the cancer stem cells (CSCs, TICs: tumor-initiating cells) killing
activity of EndoCD/5-FC.
Clinical data now suggest that antiangiogenic therapy leads to the
progression of tumors by increasing invasion and metastasis, likely due to activation
of the cancer stem cell population (Ebos et al., 2009; Paez-Ribes et al., 2009).
Cancer stem cells (CSC, or tumor-initiating cells, TICs) have been considered to
contribute to cancer initiation, progression and chemotherapeutic resistance (Al-Hajj
and Clarke, 2004; Reya et al., 2001; Rossi et al., 2008). It has also been shown that
glioma initiating cells have a greater ability to promote vascular endothelial growth
which may confer enhanced angiogenesis for tumor cell survival and proliferation
(Ricci-Vitiani et al., 2010; Wang et al., 2010b). Currently, there are no effective ways
to target CSCs. CSCs in different types of cancer have been gradually identified.
For example, breast cancer stem cells (BCSCs, alternatively called breast tumor
initiation cells, BTICs) can be isolated by sorting for CD44+CD24-/low cells (Al-Hajj
et al., 2003) or Hoechst negative side population (SP) cells (Patrawala et al., 2005),
and can also be enriched by spheroid culture and serial transplantations in
immunodeficient mice (Ponti et al., 2005). These CSCs not only harbor the capability
of self-renewal, but also are able to differentiate into multiple lineages of tumor cells
growing in various types of distal organs. They have been shown to be resistant to
the standard chemotherapy. Thus, we hypothesized that EndoCD/5-FC may
selectively reduce breast cancer stem cells populations.

10.2.1 To determine EndoCD/5-FC CSCs killing activities
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After EndoCD/5-FC protein treatment, we found that EndoCD/5-FC
selectively reduced the MDA-MB-231 and MCF-7 CD44+/CD24- population in a dose
dependent manner (Figure 20A) as well as mammosphere formation (Figure 20B).
These results suggest that EndoCD/5-FC may inhibit BCSC growth. We will expand
the experiments to multiple breast cancer cell lines even primary tumor samples with
different criteria of CSC phenomena in vitro and in vivo. The molecular mechanism
for EndoCD/5FC-mediated BCSCs suppression should be interesting to further
pursue. For instance, if Endo is critical for targeting BCSCs, integrin αvβ1 in BCSCs
may be important for maintenance of BCSC. Once it becomes clear, we will logically
pursue the appropriate direction. Alternatively, we can always use a nonbiased
approach such as antibody arrays to identify which signal pathways might be
activated/inactivated by EndoCD/5-FC treatment.
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Figure 20. EndoCD/5-FC can selectively reduce breast cancer stem cell
population.

(A) To detect the CSC (TICs) population, surface markers CD44+/CD24- serve as
an index. After EndoCD/5-FC treatment in two human breast cancer cell lines (MDAMB-231 and MCF-7) for 48 hours, 1X106 cells were processed for staining with
FITC-conjugated CD44 and PE-conjugated CD24 antibodies, respectively, and then
analyzed or sorted with BD flow cytometer. EndoCD/5-FC decreased breast stem
cell population by dose dependent manner.

(B) CSC (TICs) population was also validated by culturing mammospheres using
MammoCultTM medium containing 4 ug/ml Heparin and 0.48 μg/ml hydrocortisone.
EndoCD/5-FC has ability to inhibit breast cancer mammopheres formation.
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Figure 20.
A.MDA-MB-231

MCF-7

B.
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